River 2 Renal Corp.

4 trials 2 recruiting Commercial sponsor Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

6 Countries active

6 Unique IMPs

100% Results reported

Phase II

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Alport's syndrome 1 Focal segmental glomerulosclerosis 1

Top IMPs

R2R01 2 R3R01 2 PENTETIC ACID 1 SODIUM CHLORIDE 1

All trials

4 total

A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High R… Recruiting

2025-523037-25-00 Phase II 2 countries R2R01; SODIUM CHLORIDE
Kidney ABC Recruiting

2024-511484-29-00 Phase II 1 country PENTETIC ACID; R3R01
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist… Ended

2023-503504-88-00 Phase II 2 countries R2R01
R3R01 in Alport Syndrome Patients and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis Ended

2024-512964-73-00 Phase II 4 countries R3R01

Showing 1–4 of 4 trials

← All sponsors A–Z